Payment overview · 2025
General Payments
$345.03
16 reported records · 11 companies
Healthcare provider profile · identity verified
Viplav Narayan Deogaonkar
Allopathic & Osteopathic Physicians|Internal Medicine · PRINCE FREDERICK, MD · NPI 1609339050
Verified facts
What the public records show
CMS Open Payments records show Viplav Narayan Deogaonkar received $345.03 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.04 | 18.3% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.70 | 12.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.02 | 11.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.10 | 10.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.30 | 9.9% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $25.91 | 7.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.79 | 7.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.18 | 6.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.27 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.84 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.88 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $345.03 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $40.14 | 2 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $34.30 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 362 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 73 |
| Lisinopril | Lisinopril | 191 | 58 |
| Losartan Potassium | Losartan Potassium | 185 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 50 |
| Chlorthalidone | Chlorthalidone | 150 | 55 |
| Gabapentin | Gabapentin | 139 | 47 |
| Metformin Hcl Er | Metformin Hcl | 119 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 47 |
| Eliquis | Apixaban | 114 | 32 |
| Furosemide | Furosemide | 111 | 49 |
| Omeprazole | Omeprazole | 111 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 35 |
| Tramadol Hcl | Tramadol Hcl | 94 | 32 |
| Carvedilol | Carvedilol | 91 | 32 |
| Azithromycin | Azithromycin | 89 | 70 |
| Potassium Chloride | Potassium Chloride | 87 | 37 |
| Allopurinol | Allopurinol | 83 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 25 |
| Prednisone | Prednisone | 70 | 54 |
| Alprazolam | Alprazolam | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 24 |
| Nifedipine Er | Nifedipine | 59 | 21 |
| Sertraline Hcl | Sertraline Hcl | 58 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 28 |
| Metformin Hcl | Metformin Hcl | 55 | 22 |
| Ozempic | Semaglutide | 51 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Irbesartan | Irbesartan | 45 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 17 |
| Trazodone Hcl | Trazodone Hcl | 40 | 17 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Famotidine | Famotidine | 38 | 16 |
| Glipizide | Glipizide | 38 | 16 |
| Finasteride | Finasteride | 37 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 16 |
| Atenolol | Atenolol | 35 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Ibuprofen | Ibuprofen | 34 | 17 |
| Spironolactone | Spironolactone | 34 | 15 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 16 |
| Ofloxacin | Ofloxacin | 28 | 22 |
| Simvastatin | Simvastatin | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Amoxicillin | Amoxicillin | 25 | 21 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | 16 |
| Diazepam | Diazepam | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $345.03 · 16 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BOTOX, COMIRNATY, Cologuard Collection Kit, Cresemba, Flexitouch Plus, Kerendia, Korlym, LINZESS, Nimbl, PREVNAR 20, QULIPTA, TEZSPIRE, VELSIPITY, VIBERZI, XELJANZ, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error